Old Web
English
Sign In
Acemap
>
authorDetail
>
Frank van Aarle
Frank van Aarle
Merck & Co.
Medicine
Antibody
in patient
Tildrakizumab
Psoriasis
4
Papers
163
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Impact of patient characteristics on the pharmacokinetics of corifollitropin alfa during controlled ovarian stimulation.
2016
British Journal of Clinical Pharmacology
Anthe S. Zandvliet
Marita Prohn
Rik de Greef
Frank van Aarle
Christine McCrary Sisk
Barbara J. Stegmann
Show All
Source
Cite
Save
Citations (1)
Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and non-small cell lung cancer (NSCLC): Pooled results from KEYNOTE-001, 002, 006, and 010.
2016
Journal of Clinical Oncology
Marianne van Vugt
Rik de Greef
Tomoko Freshwater
Eric Mangin
Frank van Aarle
Anna Kondic
Show All
Source
Cite
Save
Citations (10)
Clinical improvement in psoriasis with specific targeting of interleukin-23
2015
Nature
Tamara Kopp
Elisabeth Riedl
Christine Bangert
Edward P. Bowman
Elli K. Greisenegger
Ann Horowitz
Harald Kittler
Wendy M. Blumenschein
Terrill K. McClanahan
Thomas Marbury
Claus Zachariae
Danlin Xu
Xiaoli Shirley Hou
Anish Mehta
Anthe S. Zandvliet
Diana Montgomery
Frank van Aarle
Sauzanne Khalilieh
Show All
Source
Cite
Save
Citations (152)
A Rising Multiple-Dose Tolerability, Safety, and Pharmacokinetic Study of Intravenous Tildrakizumab in Patients With Psoriasis
2015
Tamara Kopp
Elisabeth Riedl
Christine Bangert
Edward Bowman
Elli K. Greisenegger
Ann Horowitz
Harald Kittler
Wendy M. Blumenschein
Terrill K. Mcclanahan
Thomas Marbury
Claus Zachariae
Danlin Xu
Xiaoli Shirley Hou
Anish Mehta
Anthe S. Zandvliet
Diana Montgomery
Frank van Aarle
Sauzanne Khalilieh
Show All
Source
Cite
Save
Citations (0)
1
map